Cited 1 times in
Survival benefit of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in female with advanced lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박유랑 | - |
dc.date.accessioned | 2019-09-20T07:47:03Z | - |
dc.date.available | 2019-09-20T07:47:03Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0300-8916 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/171050 | - |
dc.description.abstract | BACKGROUND: This study aimed to estimate therapeutic effects of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in real-world practice, by analyzing survival outcomes in an unselected, Korean female population with advanced lung cancer based on the National Health Insurance Service database. METHODS: We identified women with newly diagnosed advanced lung cancer from January 2004 to December 2013. For progression-free survival (PFS) and overall survival (OS) analyses, patients were defined into the following subgroups: group A, treated with first-generation EGFR-TKI ⩾6 months; group B, treated with EGFR-TKIs <6 months but at least >1 month; and group C, treated with cytotoxic chemotherapy as follows: monotherapy or combination therapy with gemcitabine or pemetrexed; or monotherapy with docetaxel, paclitaxel, or vinorelbine. RESULTS: Among 11,045 enrolled patients, 6170 (55.8%) were treated with first-generation EGFR-TKIs for at least 1 month. The median OS for patients treated with EGFR-TKIs was significantly longer than that of EGFR-TKI-naive patients (19.1 months [95% confidence interval (CI) 18.5-19.7] vs 9.5 months [95% CI 9.1-9.8], P<0.001). In subgroup analysis, group A had a significantly longer median OS compared with group B (30.3 months [95% CI 29.5-31.2] vs 12.3 months [95% CI 11.9-12.7], P<0.001). The median PFS of group A was significantly longer than that of group B (15.8 vs 3.7 months, P<0.001). CONCLUSIONS: Our analysis demonstrates that EGFR-TKIs confer significant PFS and OS benefits in the real-world practice for Korean female with advanced lung cancer. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | Italian, English | - |
dc.publisher | Wichtig Publishing | - |
dc.relation.isPartOf | Tumori | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives | - |
dc.subject.MESH | ErbB Receptors/genetics | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms/drug therapy* | - |
dc.subject.MESH | Lung Neoplasms/epidemiology | - |
dc.subject.MESH | Lung Neoplasms/genetics | - |
dc.subject.MESH | Lung Neoplasms/pathology | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Pemetrexed/administration & dosage | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Protein Kinase Inhibitors/administration & dosage* | - |
dc.title | Survival benefit of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in female with advanced lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) | - |
dc.contributor.googleauthor | Byoung Soo Kwon | - |
dc.contributor.googleauthor | Ji Hyun Park | - |
dc.contributor.googleauthor | Seulgi Kim | - |
dc.contributor.googleauthor | Sojung Park | - |
dc.contributor.googleauthor | Wonjun Ji | - |
dc.contributor.googleauthor | Woo Sung Kim | - |
dc.contributor.googleauthor | Jae Cheol Lee | - |
dc.contributor.googleauthor | Yu Rang Park | - |
dc.contributor.googleauthor | Chang-Min Choi | - |
dc.identifier.doi | 10.1177/0300891619839292 | - |
dc.contributor.localId | A05624 | - |
dc.relation.journalcode | J02764 | - |
dc.identifier.eissn | 2038-2529 | - |
dc.identifier.pmid | 30905312 | - |
dc.identifier.url | https://journals.sagepub.com/doi/full/10.1177/0300891619839292 | - |
dc.subject.keyword | Advanced lung cancer | - |
dc.subject.keyword | EGFR-TKI | - |
dc.subject.keyword | Korea | - |
dc.subject.keyword | big data | - |
dc.subject.keyword | female | - |
dc.contributor.alternativeName | Park, Yu Rang | - |
dc.contributor.affiliatedAuthor | 박유랑 | - |
dc.citation.volume | 105 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 216 | - |
dc.citation.endPage | 224 | - |
dc.identifier.bibliographicCitation | Tumori, Vol.105(3) : 216-224, 2019 | - |
dc.identifier.rimsid | 63367 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.